EUCTR2015-002241-55-GB进行中（未招募）1 期
A phase II trial of pembrolizumab in patients with non-small cell lung cancer and a performance status of 2 - A phase II trial of pembrolizumab in NSCLC PS2 patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must have completed all standard of care therapy that the treating oncologist deems appropriate. All lines of therapy will be allowed.
- •Histologically confirmed NSCLC where it is possible to assess PD-L1 status on tumour biopsy. Biopsy must be within 70 days of first treatment with pembrolizumab. All patients who have had systemic therapy since the biopsy must have a repeat biopsy that is evaluable for PD-L1.
- •Patients must have a performance status of 2 on the ECOG Performance scale with no deterioration over the previous 2 weeks assessed by consenting physician.
- •Life expectancy >12 weeks.
- •Uni-dimensionally measurable disease according to RECIST v1.1.
- •CT scan of chest and abdomen within 28 days of starting Pembrolizumab demonstrating measurable disease as per RECIST version 1.1.
- •Demonstrate adequate haematological and organ function as defined below. All screening tests should be performed within 7 days of treatment.
- •Age = 18 years.
- •Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
- •Patients must agree to the use of contraception as detailed in protocol and patient information sheet
- •System Laboratory Value
- •Haematological
- •Absolute neutrophil count = 1.5 x 109/L.
- •Haemoglobin = 90 g/L or =5.6 mmol/L.
- •Platelets = 100 x 109/L
- •Hepatic function
- •Total serum bilirubin = 1.5 x ULN
- •Alanine transferase (ALT) = 2.5 x ULN.
- •Aspartate transferase (AST) = 2.5 x ULN.
- •Renal function
- •Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min (calculated by Cockcroft and Gault equation or alternative method). If this is =50 ml/min then an isotopic GFR may be undertaken and must be >50 ml/min
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Untreated symptomatic brain or leptomeningeal metastatic disease.
- •Medical or psychiatric conditions comprising informed consent.
- •Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.
- •Patient who has had chemotherapy, radioactive or biological cancer therapy within 4 weeks prior to the first dose of study therapy, or who has not recovered to CTCAE grade 1 or better from the adverse events due to cancer therapeutics administered more than 4 weeks earlier. Patient who has had erlotinib, gefitinib, afatinib, or crizotinib within 1 week prior to the first dose of study therapy, or who has not recovered to CTCAE Grade 1 or better from the adverse events due to any of these drugs administered more than 1 week earlier. Patient who has had ipilimumab therapy may be enrolled if requirements specified in Inclusion Criterion are met.
- •Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Patient has risk factors for bowel obstruction or bowel perforation (examples include but not limited to a history of acute diverticulitis, intra-abdominal abscess and abdominal carcinomatosis).
- •Patient has a known history of malignancy, unless the patient has undergone potentially curative therapy with no evidence of that disease for 5 years.
- •Previous history of pneumonitis or significantly reduced transfer coefficient (KCO).
- •Female patients of child bearing potential should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing.
- •Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
- •Patient had prior treatment targeting PD-1: PD-L1 axis or was previously randomized in any Pembrolizumab trial.
- •Patient is positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA (qualitative) is detected); patients with negative Hepatitis C antibody testing may not need RNA testing.
- •Known history of tuberculosis
- •Patient has an active infection requiring therapy.
- •Has received a live vaccine within 30 days prior to the first dose of trial treatment.
- •Patient is, at the time of signing informed consent, a regular user (including recreational use”) of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
- •Patients with symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
研究者
相似试验
进行中（未招募）
1 期
A clinical study testing the effectiveness of an immunotherapy cancer drug called pembrolizumab, in patients who have progressed with gynaecological cancer, called clear cell cancer.Advanced Gynaecological Clear Cell CancerMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10009252Term: Clear cell endometrial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10046885Term: Vaginal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10047741Term: Vulval cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004168-36-GBniversity College London48
进行中（未招募）
1 期
A phase II study of pembrolizumab in patients with malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgeryMalignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgeryEUCTR2015-004747-39-NOOslo University Hospital18
招募中
不适用
Phase II study of pembrolizumab in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine: integration of molecular subtypes through integrative genomic analysis.NeoplasmsKCT0003562Samsung Medical Center40
进行中（未招募）
1 期
PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgeryEUCTR2016-001676-29-ITOSLO UNIVERSITETSSYKEHUS HF25
进行中（未招募）
1 期
PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgeryEUCTR2016-001676-29-NOOslo University Hospital (OUS)25